|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
CA2371427A1
(en)
|
1999-04-28 |
2000-11-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
|
|
WO2001075110A2
(en)
|
2000-03-30 |
2001-10-11 |
Dyax Corp. |
Mucin-1 specific binding members and methods of use thereof
|
|
DE10303664A1
(de)
|
2003-01-23 |
2004-08-12 |
Nemod Immuntherapie Ag |
Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
|
|
WO2005086875A2
(en)
*
|
2004-03-11 |
2005-09-22 |
City Of Hope |
A humanized anti-cea t84.66 antibody and uses thereof
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
WO2007019232A2
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
EA015860B1
(ru)
*
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
EP2083868A2
(en)
|
2006-10-04 |
2009-08-05 |
Københavns Universitet |
Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
|
|
JP5773352B2
(ja)
|
2008-10-28 |
2015-09-02 |
塩野義製薬株式会社 |
抗ｍｕｃ１抗体
|
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
CA2803520C
(en)
|
2009-07-08 |
2019-10-22 |
Lantheus Medical Imaging, Inc. |
N-alkoxyamide conjugates as imaging agents
|
|
EP2281844A1
(en)
|
2009-07-31 |
2011-02-09 |
Glycotope GmbH |
MUC 1 antibodies
|
|
EP3009455A1
(en)
|
2009-09-16 |
2016-04-20 |
Immunomedics Inc. |
Class i anti-cea antibodies and uses thereof
|
|
KR101809761B1
(ko)
|
2009-09-24 |
2017-12-15 |
가부시키가이샤 진 테크노 사이언스 |
세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
|
|
EP2347769A1
(en)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Cancer stem cell markers and uses thereof
|
|
EP2565268A4
(en)
|
2010-04-28 |
2013-10-09 |
Shionogi & Co |
NEW MUC1 ANTIBODY
|
|
CN101928347B
(zh)
|
2010-05-05 |
2013-03-27 |
上海海抗中医药科技发展有限公司 |
抗癌胚抗原抗体及其应用
|
|
WO2012015912A1
(en)
*
|
2010-07-30 |
2012-02-02 |
Medimmune, Llc |
Method for purifying active polypeptides or immunocojugates
|
|
RS56793B1
(sr)
|
2011-03-02 |
2018-04-30 |
Roche Glycart Ag |
Cea antitela
|
|
WO2013081091A1
(ja)
|
2011-12-01 |
2013-06-06 |
国立大学法人 千葉大学 |
非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
|
|
HUE033369T2
(en)
|
2012-11-20 |
2017-11-28 |
Sanofi Sa |
Anti-ceacam5 antibodies and uses thereof
|
|
US9429584B2
(en)
|
2013-02-28 |
2016-08-30 |
National Cancer Center |
Antibody against insoluble fibrin
|
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
|
|
NL1040254C2
(en)
*
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
KR102313341B1
(ko)
|
2013-08-26 |
2021-10-18 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
|
|
TWI541022B
(zh)
|
2013-12-18 |
2016-07-11 |
應克隆公司 |
針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
|
|
CN106132434A
(zh)
*
|
2014-04-07 |
2016-11-16 |
西雅图基因公司 |
抗‑cd19抗体和抗体‑药物偶联物的稳定制剂
|
|
AU2015254257B2
(en)
|
2014-04-28 |
2021-02-25 |
Medicinal Chemistry Pharmaceuticals, Co., Ltd. |
Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
|
|
TWI738632B
(zh)
*
|
2014-11-07 |
2021-09-11 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
CA2976089C
(en)
|
2015-02-10 |
2026-01-13 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
|
MX2018007520A
(es)
*
|
2015-12-18 |
2018-08-01 |
Astellas Pharma Inc |
Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.
|
|
JOP20170017B1
(ar)
*
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
WO2017150549A1
(ja)
|
2016-03-01 |
2017-09-08 |
国立大学法人 千葉大学 |
放射性標識薬剤
|
|
JPWO2017164349A1
(ja)
*
|
2016-03-25 |
2019-02-07 |
アステラス製薬株式会社 |
ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物
|
|
GEP20217249B
(en)
*
|
2016-06-30 |
2021-04-26 |
Inc Celltrion |
Stable liquid pharmaceutical preparation
|
|
TWI780082B
(zh)
|
2016-11-18 |
2022-10-11 |
日商安斯泰來製藥股份有限公司 |
新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
|
|
US10758632B2
(en)
|
2017-02-06 |
2020-09-01 |
City Of Hope |
NIR-conjugated tumor-specific antibodies and uses thereof
|
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
|
|
JP7207740B2
(ja)
|
2017-09-26 |
2023-01-18 |
国立大学法人千葉大学 |
放射性薬剤
|
|
MX2020012351A
(es)
|
2018-05-17 |
2021-01-29 |
Astellas Pharma Inc |
Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
|
|
CA3115747A1
(en)
|
2018-10-10 |
2020-04-16 |
Astellas Pharma Inc. |
Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
|
|
JPWO2020145228A1
(ja)
|
2019-01-07 |
2021-11-11 |
アステラス製薬株式会社 |
配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体
|